- Home
- JKS vs TRVI Comparison
JKS vs TRVI Comparison
Compare JKS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKS | TRVI |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JKS | TRVI |
|---|---|---|
| Price | $23.51 | $10.50 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $22.33 | $21.55 |
| AVG Volume (30 Days) | 421.1K | ★ 1.1M |
| Earning Date | 04-28-2026 | 03-17-2026 |
| Dividend Yield | ★ 5.48% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.42 | $4.85 |
| 52 Week High | $31.88 | $14.39 |
Technical Indicators
Market Signals| Indicator | JKS | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 38.56 |
| Support Level | $21.38 | $10.04 |
| Resistance Level | $23.76 | $11.78 |
| Average True Range (ATR) | 0.90 | 0.74 |
| MACD | -0.10 | -0.20 |
| Stochastic Oscillator | 15.22 | 1.26 |
Price Performance
Historical ComparisonAbout JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.